Online inquiry

IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9947MR)

This product GTTS-WQ9947MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets hly gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033
UniProt ID P09616
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9947MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2336MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ11013MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9996MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ10444MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ14966MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ14486MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ14404MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ793MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW